<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Exicure Inc — News on 6ix</title>
<link>https://6ix.com/company/exicure-inc</link>
<description>Latest news and press releases for Exicure Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 22 Apr 2026 23:54:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/exicure-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835da7c78dffbe2df123794.webp</url>
<title>Exicure Inc</title>
<link>https://6ix.com/company/exicure-inc</link>
</image>
<item>
<title>Exicure Announces Co-Development Agreement with Adbiotech for Burixafor (GPC-100)</title>
<link>https://6ix.com/company/exicure-inc/news/exicure-announces-co-development-agreement-with-adbiotech-for-burixafor-gpc-100</link>
<guid isPermaLink="true">https://6ix.com/company/exicure-inc/news/exicure-announces-co-development-agreement-with-adbiotech-for-burixafor-gpc-100</guid>
<pubDate>Wed, 22 Apr 2026 23:54:00 GMT</pubDate>
<description>CHICAGO, April 22, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR) today announced that it has entered into a co-development agreement with Adbiotech Co., Ltd. (KOSDAQ: 179530), a Korea-based biotechnology company, to explore combination therapies based on Burixafor (GPC-100) across multiple therapeutic areas. The collaboration will focus on evaluating combination strategies involving Burixafor (GPC-100) in indications including sickle cell disease (SCD), acute myeloid leukemia (AML), and</description>
</item>
<item>
<title>Exicure, Inc. Reports Full Year 2025 Financial Results</title>
<link>https://6ix.com/company/exicure-inc/news/exicure-inc-reports-full-year-2025-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/exicure-inc/news/exicure-inc-reports-full-year-2025-financial-results</guid>
<pubDate>Wed, 25 Mar 2026 20:18:00 GMT</pubDate>
<description>REDWOOD CITY, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR, the “Company”) releases the following financial results for the year ended December 31, 2025. 2025 Financial Results Cash Position: Cash and cash equivalents were $3.7 million as of December 31, 2025, compared to $12.5 million as of December 31, 2024. Our current liquidity may not be sufficient to fund operations for the next 12 months. Additional financing will be required to support ongoing operations, contin</description>
</item>
<item>
<title>Exicure Announces Publication in Annals of Hematology Highlighting Rapid Stem Cell Mobilization with Burixafor in Patients with Multiple Myeloma and Lymphoma Undergoing Transplant</title>
<link>https://6ix.com/company/exicure-inc/news/exicure-announces-publication-in-annals-of-hematology-highlighting-rapid-stem-cell-mobilization-with-burixafor-in-patients-with-multiple-myeloma-and-lymphoma-undergoing-transplant</link>
<guid isPermaLink="true">https://6ix.com/company/exicure-inc/news/exicure-announces-publication-in-annals-of-hematology-highlighting-rapid-stem-cell-mobilization-with-burixafor-in-patients-with-multiple-myeloma-and-lymphoma-undergoing-transplant</guid>
<pubDate>Thu, 05 Feb 2026 12:00:00 GMT</pubDate>
<description>Phase 2 data demonstrate differentiated CXCR4 inhibition kinetics enabling same-day cell collection, with rapid lymphocyte mobilization supporting potential therapeutic applications beyond transplantREDWOOD CITY, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today announced the publication of results from a prior Phase 2 clinical study evaluating burixafor (GPC-100/TG-0054), a highl</description>
</item>
<item>
<title>Exicure to Present Data from Burixafor Phase 2 Trial at the 2026 Tandem Meetings</title>
<link>https://6ix.com/company/exicure-inc/news/exicure-to-present-data-from-burixafor-phase-2-trial-at-the-2026-tandem-meetings</link>
<guid isPermaLink="true">https://6ix.com/company/exicure-inc/news/exicure-to-present-data-from-burixafor-phase-2-trial-at-the-2026-tandem-meetings</guid>
<pubDate>Wed, 21 Jan 2026 12:00:00 GMT</pubDate>
<description>REDWOOD CITY, Calif., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today announced that it will present a poster at the upcoming 2026 Tandem Meetings | Transplantation & Cellular Therapy Meetings of the American Society for Transplantation and Cellular Therapy (ASTCT) and Center for International Blood and Marrow Transplant Research (CIBMTR), taking place February 4-7, 2026, in Salt Lake C</description>
</item>
<item>
<title>Exicure Presents Positive Topline Phase 2 Data for Burixafor in Multiple Myeloma at 2025 ASH Annual Meeting</title>
<link>https://6ix.com/company/exicure-inc/news/exicure-presents-positive-topline-phase-2-data-for-burixafor-in-multiple-myeloma-at-2025-ash-annual-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/exicure-inc/news/exicure-presents-positive-topline-phase-2-data-for-burixafor-in-multiple-myeloma-at-2025-ash-annual-meeting</guid>
<pubDate>Mon, 08 Dec 2025 21:30:00 GMT</pubDate>
<description>REDWOOD CITY, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today announced positive results from its completed Phase 2 trial evaluating burixafor (GPC-100) in combination with propranolol and granulocyte colony-stimulating factor (G-CSF) for the mobilization of hematopoietic progenitor cells (HPCs) in patients with multiple myeloma undergoing autologous hematopoietic cell transplan</description>
</item>
<item>
<title>Exicure, Inc. Reports Third Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/exicure-inc/news/exicure-inc-reports-third-quarter-2025-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/exicure-inc/news/exicure-inc-reports-third-quarter-2025-financial-results</guid>
<pubDate>Fri, 07 Nov 2025 21:00:00 GMT</pubDate>
<description>REDWOOD CITY, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR, the “Company”) releases the following financial results for the fiscal quarter ended September 30, 2025. Third Quarter 2025 Financial Results Cash Position: Cash and cash equivalents were $4.4 million as of September 30, 2025, as compared to $12.5 million as of December 31, 2024. Research and Development (R&D) Expense: Research and development expenses were $0.9 million for the quarter ended September 30, 2025,</description>
</item>
<item>
<title>New Burixafor Clinical Data to be Presented as an Oral Presentation at the 2025 ASH Annual Meeting</title>
<link>https://6ix.com/company/exicure-inc/news/new-burixafor-clinical-data-to-be-presented-as-an-oral-presentation-at-the-2025-ash-annual-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/exicure-inc/news/new-burixafor-clinical-data-to-be-presented-as-an-oral-presentation-at-the-2025-ash-annual-meeting</guid>
<pubDate>Mon, 03 Nov 2025 14:00:00 GMT</pubDate>
<description>REDWOOD CITY, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today announced that results from its completed Phase 2 study evaluating burixafor, a small molecule CXCR4 antagonist, will be featured in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, taking place December 6-9, 2025, in Orlando, Florida. The presentation will highlight</description>
</item>
<item>
<title>Exicure Highlights Recent Achievements and Near-term Strategic Priorities</title>
<link>https://6ix.com/company/exicure-inc/news/exicure-highlights-recent-achievements-and-near-term-strategic-priorities</link>
<guid isPermaLink="true">https://6ix.com/company/exicure-inc/news/exicure-highlights-recent-achievements-and-near-term-strategic-priorities</guid>
<pubDate>Mon, 06 Oct 2025 11:00:00 GMT</pubDate>
<description>Burixafor (GPC-100) Phase 2 Trial in Multiple Myeloma Nears Key Readout Preparing for Expansion into Sickle Cell Disease and Acute Myeloid Leukemia New Leadership Appointments Bring Deep Drug Development Expertise REDWOOD CITY, Calif., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today shared recent progress for its lead program, burixafor (GPC-100), outlined upcoming strategic priorities,</description>
</item>
<item>
<title>Exicure, Inc. Reports Second Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/exicure-inc/news/exicure-inc-reports-second-quarter-2025-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/exicure-inc/news/exicure-inc-reports-second-quarter-2025-financial-results</guid>
<pubDate>Fri, 08 Aug 2025 20:01:00 GMT</pubDate>
<description>REDWOOD CITY, Calif., August 08, 2025--Exicure, Inc. Reports Second Quarter 2025 Financial Results</description>
</item>
<item>
<title>Exicure, Inc. (Nasdaq: XCUR) Regains Compliance with Nasdaq Filing Requirements</title>
<link>https://6ix.com/company/exicure-inc/news/exicure-inc-nasdaq-xcur-regains-compliance-with-nasdaq-filing-requirements</link>
<guid isPermaLink="true">https://6ix.com/company/exicure-inc/news/exicure-inc-nasdaq-xcur-regains-compliance-with-nasdaq-filing-requirements</guid>
<pubDate>Mon, 04 Aug 2025 20:37:00 GMT</pubDate>
<description>REDWOOD CITY, Calif., August 04, 2025--Exicure, Inc. (Nasdaq: XCUR) Regains Compliance with Nasdaq Filing Requirements</description>
</item>
<item>
<title>Exicure Completes the Last Patient, Last Visit in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous Transplant</title>
<link>https://6ix.com/company/exicure-inc/news/exicure-completes-the-last-patient-last-visit-in-phase-2-study-of-gpc-100-for-stem-cell-mobilization-in-multiple-myeloma-patients-undergoing-autologous-transplant</link>
<guid isPermaLink="true">https://6ix.com/company/exicure-inc/news/exicure-completes-the-last-patient-last-visit-in-phase-2-study-of-gpc-100-for-stem-cell-mobilization-in-multiple-myeloma-patients-undergoing-autologous-transplant</guid>
<pubDate>Fri, 01 Aug 2025 20:01:00 GMT</pubDate>
<description>REDWOOD CITY, Calif., August 01, 2025--Exicure Completes the Last Patient, Last Visit in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients</description>
</item>
<item>
<title>Exicure, Inc. Reports First Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/exicure-inc/news/exicure-inc-reports-first-quarter-2025-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/exicure-inc/news/exicure-inc-reports-first-quarter-2025-financial-results</guid>
<pubDate>Fri, 27 Jun 2025 20:01:00 GMT</pubDate>
<description>REDWOOD CITY, Calif., June 27, 2025--Q1 2025 earnings release</description>
</item>
<item>
<title>Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-Q</title>
<link>https://6ix.com/company/exicure-inc/news/exicure-inc-received-nasdaq-delinquency-notice-on-late-filing-of-its-form-10-q</link>
<guid isPermaLink="true">https://6ix.com/company/exicure-inc/news/exicure-inc-received-nasdaq-delinquency-notice-on-late-filing-of-its-form-10-q</guid>
<pubDate>Wed, 28 May 2025 20:58:00 GMT</pubDate>
<description>REDWOOD CITY, Calif., May 28, 2025--Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-Q</description>
</item>
<item>
<title>Exicure Completes Patient Enrollment in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous Transplant</title>
<link>https://6ix.com/company/exicure-inc/news/exicure-completes-patient-enrollment-in-phase-2-study-of-gpc-100-for-stem-cell-mobilization-in-multiple-myeloma-patients-undergoing-autologous-transplant</link>
<guid isPermaLink="true">https://6ix.com/company/exicure-inc/news/exicure-completes-patient-enrollment-in-phase-2-study-of-gpc-100-for-stem-cell-mobilization-in-multiple-myeloma-patients-undergoing-autologous-transplant</guid>
<pubDate>Mon, 05 May 2025 12:00:00 GMT</pubDate>
<description>REDWOOD CITY, Calif., May 05, 2025--Exicure Completes Patient Enrollment in Phase 2 Study of GPC-100 Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous Transplant</description>
</item>
<item>
<title>Exicure, Inc. (Nasdaq: XCUR) Nears Completion of Phase 2 Study of GPC-100 in Multiple Myeloma</title>
<link>https://6ix.com/company/exicure-inc/news/exicure-inc-nasdaq-xcur-nears-completion-of-phase-2-study-of-gpc-100-in-multiple-myeloma</link>
<guid isPermaLink="true">https://6ix.com/company/exicure-inc/news/exicure-inc-nasdaq-xcur-nears-completion-of-phase-2-study-of-gpc-100-in-multiple-myeloma</guid>
<pubDate>Mon, 14 Apr 2025 22:11:00 GMT</pubDate>
<description>REDWOOD CITY, Calif., April 14, 2025--Exicure, Inc. Nears Completion of Phase 2 Study of GPC-100 in Multiple Myeloma</description>
</item>
<item>
<title>Exicure, Inc. (Nasdaq: XCUR) Announces Their Next Step in Planning for a New Clinical Trial in Acute Myeloid Leukemia (AML)</title>
<link>https://6ix.com/company/exicure-inc/news/exicure-inc-nasdaq-xcur-announces-their-next-step-in-planning-for-a-new-clinical-trial-in-acute-myeloid-leukemia-aml</link>
<guid isPermaLink="true">https://6ix.com/company/exicure-inc/news/exicure-inc-nasdaq-xcur-announces-their-next-step-in-planning-for-a-new-clinical-trial-in-acute-myeloid-leukemia-aml</guid>
<pubDate>Fri, 11 Apr 2025 23:42:00 GMT</pubDate>
<description>REDWOOD CITY, Calif., April 11, 2025--Exicure, Inc. Announces Their Next Step in Planning for a New Clinical Trial in Acute Myeloid Leukemia (AML)</description>
</item>
<item>
<title>Exicure, Inc. Reports Full Year 2024 Financial Results</title>
<link>https://6ix.com/company/exicure-inc/news/exicure-inc-reports-full-year-2024-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/exicure-inc/news/exicure-inc-reports-full-year-2024-financial-results</guid>
<pubDate>Tue, 18 Mar 2025 20:01:00 GMT</pubDate>
<description>CHICAGO, March 18, 2025--Exicure, Inc. Reports Full Year 2024 Financial Results</description>
</item>
<item>
<title>Exicure, Inc. (Nasdaq: XCUR) Announces Issuance of New Patent in Australia</title>
<link>https://6ix.com/company/exicure-inc/news/exicure-inc-nasdaq-xcur-announces-issuance-of-new-patent-in-australia</link>
<guid isPermaLink="true">https://6ix.com/company/exicure-inc/news/exicure-inc-nasdaq-xcur-announces-issuance-of-new-patent-in-australia</guid>
<pubDate>Thu, 13 Mar 2025 20:08:00 GMT</pubDate>
<description>CHICAGO, March 13, 2025--Exicure, Inc. Announces Issuance of New Patent in Australia</description>
</item>
<item>
<title>CORRECTING and REPLACING Exicure, Inc. Announces Purchase Agreement with GPCR Therapeutics Inc.</title>
<link>https://6ix.com/company/exicure-inc/news/correcting-and-replacing-exicure-inc-announces-purchase-agreement-with-gpcr-therapeutics-inc</link>
<guid isPermaLink="true">https://6ix.com/company/exicure-inc/news/correcting-and-replacing-exicure-inc-announces-purchase-agreement-with-gpcr-therapeutics-inc</guid>
<pubDate>Wed, 22 Jan 2025 05:00:00 GMT</pubDate>
<description>CHICAGO--(BUSINESS WIRE)-- Please replace the release dated January 22, 2025 with the following corrected version due to multiple revisions. The updated</description>
</item>
<item>
<title>CORRECTING and REPLACING Exicure, Inc. Announces Shareholders Approve the $8.7 Million Equity Financing and Reports Executive Management and Board Changes</title>
<link>https://6ix.com/company/exicure-inc/news/correcting-and-replacing-exicure-inc-announces-shareholders-approve-the-dollar87-million-equity-financing-and-reports-executive-management-and-board-changes</link>
<guid isPermaLink="true">https://6ix.com/company/exicure-inc/news/correcting-and-replacing-exicure-inc-announces-shareholders-approve-the-dollar87-million-equity-financing-and-reports-executive-management-and-board-changes</guid>
<pubDate>Fri, 20 Dec 2024 05:00:00 GMT</pubDate>
<description>CHICAGO--(BUSINESS WIRE)-- Please replace the release dated December 20, 2024 with the following corrected version due to multiple revisions. The updated</description>
</item>
</channel>
</rss>